Furthermore, previous studies have reported that STING inhibition is an effective strategy for treating various inflammatory diseases in preclinical models, such as rheumatoid arthritis and multiple sclerosis.[64, 65] A recent clinical study has shown the efficacy of a cGAS‐STING inhibitor (VENT‐03) in attenuating autoimmune diseases, such as systemic lupus erythematosus.[66] However, the clinical efficacy of small molecule drugs is often compromised by their suboptimal targeting capabilities in vivo, leading to off‐target effects and reduced therapeutic effectiveness at inflamed sites. The gene discussed is STING1; the disease is systemic lupus erythematosus.